Biotechnological Institute of Chinese Materia Medica, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China.
Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou 510632, China.
Mar Drugs. 2022 Jan 29;20(2):110. doi: 10.3390/md20020110.
Colorectal carcinoma (CRC) is one of the major causes of cancer-related incidence and deaths. Here, we identified a novel antitumor peptide, P6, with a molecular weight of 2794.8 Da from a marine Chinese medicine, Reeve. The full amino acid sequence and secondary structure of P6 were determined by tandem mass de novo sequencing and circular dichroism spectroscopy, respectively. P6 markedly inhibited cell proliferation and colony formation, and induced apoptosis in CRC cells. Mechanistically, transcriptomics analysis and a serial functional evaluation showed that P6 induced colon cancer cell apoptosis through the activation of the p38-MAPK signaling pathway. Moreover, it was demonstrated that P6 exhibited antitumor effects in a tumor xenograft model, and induced cell cycle arrest in CRC cells in a concentration-dependent mode. These findings provide the first line of indication that P6 could be a potential therapeutic agent for CRC treatment.
结直肠癌(CRC)是癌症相关发病率和死亡率的主要原因之一。在这里,我们从海洋中药 Reeve 中鉴定出一种新型抗肿瘤肽 P6,其分子量为 2794.8 Da。通过串联质谱从头测序和圆二色性光谱分别确定了 P6 的全长氨基酸序列和二级结构。P6 明显抑制 CRC 细胞的增殖和集落形成,并诱导细胞凋亡。在机制上,转录组学分析和一系列功能评估表明,P6 通过激活 p38-MAPK 信号通路诱导结肠癌细胞凋亡。此外,研究还表明 P6 在肿瘤异种移植模型中具有抗肿瘤作用,并以浓度依赖的方式诱导 CRC 细胞周期停滞。这些发现为 P6 可能成为 CRC 治疗的潜在治疗剂提供了初步依据。